Developing cell and gene therapies in immuno-oncology

Get to know Elicera Therapeutics

Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer.

Di Yu, Head of Technical Operations and co-founder, tells more about Elicera in the film.

About Elicera
Cells in an immune system

Training the immune system to fight cancer

Unlike traditional cancer therapies, such as radiation, surgery and chemotherapy, immuno-oncology is about training the body's own immune system to fight cancer.

Ongoing clinical study

Uppsala University is currently sponsoring an ongoing clinical phase I/II-study with Elicera's oncolytic virus, ELC-100, in neuroendocrine tumors. In addition, a second clinical phase I/II-study with CAR T-cell therapy, ELC-301, in B-cell lymphoma, is under planning.
Scientist working with vaccines in a lab

Company Presentation

See the latest company presentation (Swedish).

Events and Presentations

Notice of interest

Register a non-binding interest to participate in Elicera's next round of financing, tentatively planned for spring 2021. We thank you for your interest and will contact you when it becomes relevant.

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Hands using syringe in a lab environment